{
    "clinical_study": {
        "@rank": "131238", 
        "arm_group": {
            "arm_group_label": "pertuzumab [Perjeta], trastuzumab [Herceptin], and taxane", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, phase III study will assess the safety, tolerability and efficacy of a\n      combination therapy of intravenous (IV) Perjeta, subcutaneous (SC) Herceptin, and taxane\n      chemotherapy (docetaxel, paclitaxel or nab-paclitaxel) as first-line therapy in patients\n      with HER2-positive metastatic breast cancer. All patients will be treated with 3-week cycles\n      of Perjeta IV (840 mg first dose; subsequent doses of 420 mg) and trastuzumab SC (600 mg/5\n      mL). The taxane treatment regimen will determined by the investigator. Patients will\n      continue therapy until disease progression, unacceptable toxicity, or the patient withdraws\n      consent, whicever occurs first. Time on study treatment is up to 2 years."
        }, 
        "brief_title": "A Study of Perjeta (Pertuzumab) and Herceptin (Trastuzumab) Treatment in Combination With a Taxane in Patients With Advanced HER2-positive Breast Cancer", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male patients aged >/= 18 years\n\n          -  HER2-positive disease, with an immunohistochemistry score of 3+ or ISH-positive on\n             primary tumour or metastatic site\n\n          -  Histologically or cytologically confirmed metastatic breast cancer (mBC) with at\n             least one measurable lesion and/or non-measurable disease according to RECIST version\n             1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 for patients who\n             will receive paclitaxel or nab-paclitaxel chemotherapy and ECOG 0-1 for patients who\n             will receive docetaxel chemotherapy\n\n          -  LVEF of >/= 50% measured by echocardiography (ECHO) or multiple-gated acquisition\n             (MUGA) scan before the first doses of pertuzumab and trastuzumab.\n\n          -  Previous use of either adjuvant or neoadjuvant anti-HER2 therapy is allowed\n\n          -  Hormonal therapy will be allowed as per institutional guidelines (administered after\n             completion of taxane chemotherapy)\n\n          -  Use of effective contraception as defined by the protocol\n\n        Exclusion Criteria:\n\n          -  Previous systemic non-hormonal anticancer therapy for treatment of mBC\n\n          -  History of other cancers. Patients with curatively treated carcinoma in situ of the\n             cervix or basal cell carcinoma and patients with other curatively-treated cancers who\n             have been disease-free for at least 5 years are eligible. Patients with previous\n             ductal carcinoma in situ (DCIS) of the breast are also eligible for the study\n\n          -  Pregnant or lactating women\n\n          -  Current peripheral neuropathy of Grade 3 or greater (National  Cancer Institute\n             Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0)\n\n          -  Radiographic evidence of central nervous system (CNS) metastases as assessed by\n             computed tomography (CT) or magnetic resonance imaging (MRI), unless they have been\n             treated and have been stable for at least 3 months and do not require ongoing\n             corticosteroid treatment\n\n          -  Patients with other concurrent serious diseases that may interfere with planned\n             treatment, including severe pulmonary conditions/illness\n\n          -  Inadequate organ function\n\n          -  Serious cardiac illness or medical conditions that would preclude the use of\n             trastuzumab\n\n          -  Patients with severe breathing difficulties at rest or requiring supplementary oxygen\n             therapy\n\n          -  Concurrent enrolment in another clinical study using an investigational anti-cancer\n             treatment, within 28 days before the first doses of Herceptin and Perjeta"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019277", 
            "org_study_id": "ML28784"
        }, 
        "intervention": [
            {
                "arm_group_label": "pertuzumab [Perjeta], trastuzumab [Herceptin], and taxane", 
                "description": "Administration of docetaxel, paclitaxel, or nab-paclitaxel. Dosing regimen to be determined by the investigator.", 
                "intervention_name": "Taxane chemotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pertuzumab [Perjeta], trastuzumab [Herceptin], and taxane", 
                "description": "Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg", 
                "intervention_name": "Perjeta (pertuzumab)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pertuzumab [Perjeta], trastuzumab [Herceptin], and taxane", 
                "description": "Subcutaneous administration of 600 mg/5 mL every 3 weeks.", 
                "intervention_name": "Herceptin (trastuzumab)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Taxane", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2050"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Macquarie", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2444"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2217"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waratah", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2298"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4101"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woolloongabba", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4102"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5112"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Launceston", 
                        "country": "Australia", 
                        "state": "Tasmania", 
                        "zip": "7250"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bendigo", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3550"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Bentleigh", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "VIC 3165"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Geelong", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3220"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3052"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murdoch", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6150"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6000"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28784 www.roche.com/about_roche/roche_worldwide..htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Therapeutic Goods Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Incidence of serious AEs", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Evidence of cardiac dysfunction as measured by decreases in left ventricular ejection fraction (LVEF).", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Progression-free survival assessed according to RECIST version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Event-free survival assessed according to RECIST version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}